论文部分内容阅读
目的探讨孟鲁司特钠联合氨溴索治疗重症喘息性肺炎的效果及安全性。方法选取2013年1月至2015年12月湖南省永州市中心医院新收治入院且符合纳入标准的重症喘息性肺炎患儿98例,随机数字法随机分为对照组及治疗组,每组49例。对照组行常规的抗感染及对症治疗,治疗组在对照组的基础上联合使用孟鲁司特钠咀嚼片、氨溴索注射液雾化吸入,观察两组患儿咳嗽、喘息、气促、肺部湿啰音及哮鸣音等主要症状体征、住院天数、总有效率等情况。结果治疗组在气促、咳嗽、喘息、肺部湿罗音、肺部哮鸣音的持续时间及住院天数等方面均短于对照组,差异均有统计学意义(P均<0.01);治疗组的总有效率为97.96%,高于对照组的83.67%,治疗组的治疗效果明显优于对照组(P<0.05);两组均未出现药物不良反应。结论孟鲁司特钠联合氨溴索佐治重症喘息性肺炎安全有效,值得临床推广。
Objective To investigate the efficacy and safety of montelukate combined with ambroxol in the treatment of severe asthmatic pneumonia. Methods From January 2013 to December 2015, 98 patients with newly diagnosed asthmatic pneumonia admitted to Central Hospital of Yongzhou, Hunan Province were enrolled and randomly divided into control group and treatment group with 49 cases in each group . Control group routine anti-infective and symptomatic treatment, the treatment group in the control group based on the combination of montelukast sodium chewable tablets, ambroxol injection inhalation, two groups of children were observed cough, wheezing, shortness of breath, Lung wet rales and wheeze and other major symptoms and signs, hospitalization days, the total efficiency and so on. Results The treatment group was shorter than the control group in the aspects of shortness of breath, cough, wheezing, lung wet rales, duration of lung wheezing and hospital stay, the differences were statistically significant (all P <0.01); treatment The total effective rate was 97.96%, which was higher than 83.67% of the control group. The therapeutic effect of the treatment group was significantly better than that of the control group (P <0.05). No adverse drug reactions occurred in both groups. Conclusion Montelukast sodium combined with ambroxol in severe asthmatic pneumonia is safe and effective, which is worthy of clinical promotion.